A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data

Drug repurposing is an effective strategy to identify new uses for existing drugs, providing the quickest possible transition from bench to bedside. Real-world data, such as electronic health records and insurance claims, provide information on large cohorts of users for many drugs. Here we present an efficient and easily customized framework for generating and testing multiple candidates for drug repurposing using a retrospective analysis of real-world data. Building upon well-established causal inference and deep learning methods, our framework emulates randomized clinical trials for drugs present in a large-scale medical claims database. We demonstrate our framework on a coronary artery disease cohort of millions of patients. We successfully identify drugs and drug combinations that substantially improve the coronary artery disease outcomes but haven’t been indicated for treating coronary artery disease, paving the way for drug repurposing. Many approved drugs can be used to treat diseases other than the one they were developed for, which has the added benefit that the safety of the drug has already been tested. To identify possible candidates for re-purposing trials, Liu et al. have developed a method to use existing electronic patient data to simulate clinical trials and identify drugs that influence the progression of diseases with which they were not previously associated.

[1]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[2]  Jürgen Schmidhuber,et al.  Long Short-Term Memory , 1997, Neural Computation.

[3]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[4]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[5]  Lin He,et al.  DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical–protein interactome , 2011, Nucleic Acids Res..

[6]  D. di Bernardo,et al.  Identification of small molecules enhancing autophagic function from drug network analysis. , 2010, Autophagy.

[7]  R. Sharan,et al.  PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.

[8]  Heng Luo,et al.  DPDR-CPI, a server that predicts Drug Positioning and Drug Repositioning via Chemical-Protein Interactome , 2016, Scientific Reports.

[9]  James M Robins,et al.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.

[10]  Ying Li,et al.  Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality , 2014, J. Am. Medical Informatics Assoc..

[11]  R. Califf,et al.  Real-World Evidence - What Is It and What Can It Tell Us? , 2016, The New England journal of medicine.

[12]  G. Imbens,et al.  Efficient Estimation of Average Treatment Effects Using the Estimated Propensity Score , 2000 .

[13]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[14]  Ralph B D'Agostino,et al.  Estimating treatment effects using observational data. , 2007, JAMA.

[15]  Philippe Sanseau,et al.  The role of translational bioinformatics in drug discovery. , 2011, Drug discovery today.

[16]  Joel Dudley,et al.  Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..

[17]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[18]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[19]  Robert Tibshirani,et al.  Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy , 1986 .

[20]  L. Cardon,et al.  Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.

[21]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[22]  Oakland J. Peters,et al.  Predicting new indications for approved drugs using a proteochemometric method. , 2012, Journal of medicinal chemistry.

[23]  R. Bonow,et al.  Chronic heart failure in the United States: a manifestation of coronary artery disease. , 1998, Circulation.

[24]  Ying Liang,et al.  Seeksv: an accurate tool for somatic structural variation and virus integration detection , 2017, Bioinform..

[25]  Jon G. Rokne,et al.  A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions , 2020, Journal of Cheminformatics.

[26]  Albert-László Barabási,et al.  Network-based approach to prediction and population-based validation of in silico drug repurposing , 2018, Nature Communications.

[27]  S. Nekolla,et al.  Effect of the Angiotensin Receptor Blocker Valsartan on Coronary Microvascular Flow Reserve in Moderately Hypertensive Patients with Stable Coronary Artery Disease , 2007, Microcirculation.

[28]  P. Austin An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[29]  Boris Freidlin,et al.  Design issues of randomized phase II trials and a proposal for phase II screening trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Mantel‐Teeuwisse,et al.  Drug repositioning and repurposing: terminology and definitions in literature. , 2015, Drug discovery today.

[31]  P. Mitchell,et al.  Fenofibrate - a potential systemic treatment for diabetic retinopathy? , 2012, American journal of ophthalmology.

[32]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[33]  G. Plotnick,et al.  Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. , 1994, Journal of the American College of Cardiology.

[34]  O. Faergeman,et al.  The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. , 1997, Journal of cardiac failure.